Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...

About 1 in every 150 people infected develops severe symptoms that can affect the brain, spinal cord and nerves.

Vizamyl is now additionally indicated for use in a selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information.

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

HealthDay News — Women who have used the oral contraceptive desogestrel (75µg) for more than 5 continuous years have a small increased risk of intracranial meningioma, according to a study published ...

HealthDay News — Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI), according to a study published online June 17 in ...

All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.

Researchers found that at week 24, 81 and 16% of the treated and control wounds, respectively, were at least 50% healed from baseline.

The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for the treatment of high-risk, Bacillus Calmette-Guérin ...

Benlysta is supplied as a single-dose prefilled autoinjector or prefilled syringe containing 200mg/mL of belimumab for SC use. The prefilled syringe has not been studied in pediatric patients aged ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...